OncoTalks | Oncology Insights at Your Fingertips

In this OncoTalks Case Journey, Dr. Paul Conkling discusses the importance of comprehensive genomic profiling and targeted therapy in non-small cell lung cancer (NSCLC).  Through the lens of two NSCLC patients who received contrasting testing and treatment, listeners learn about the actionable oncogenic biomarker ROS1, which personalized testing methods are most effective for diagnosing ROS1 varia...

Live from McKesson Accelerate 2025, Dr. Ira Zackon sits down with Dr. Martin Dietrich to discuss the latest in ROS1+ non-small cell lung cancer. They explore the rarity and significance of ROS1 mutations and clinical presentation. The conversation highlights evolving treatment strategies – from first-generation TKIs to next-generation options – plus safety profiles, resistance mechanisms, and NCCN...

Live from McKesson Accelerate 2025, host Suzzette Arnal talks with Dr. Melissa Johnson about how precision medicine is reshaping care for non-small cell lung cancer patients. They cover comprehensive biomarker testing, the role of DNA and RNA-based NGS, and why patient characteristics matter. Dr. Johnson also highlights breakthroughs in targeted therapies, emerging immunotherapies, and the critica...

In this episode of OncoTalks, Dr. Paul Conkling and Dr. Eric Nadler take a deep dive into the IMforte trial—a pivotal phase III global study evaluating lurbinectedin and atezolizumab as a first-line maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC). They unpack the trial’s design and results, highlighting key safety and efficacy data that led to the FDA’s approval of this co...

In this episode, Dr. Paul Conkling and Dr. David Spetzler explore the advantages of broad molecular profiling over smaller panels, emphasizing its superior accuracy in detecting critical biomarkers and identifying eligibility for emerging therapies. They discuss how AI is transforming treatment sequencing and improving patient outcomes, while also highlighting key technical factors—such as microdi...

In this episode of OncoTalks, Dr. Paul Conkling and Dr. Kashif Ali explore how minimal residual disease (MRD) testing using circulating tumor DNA (ctDNA) is reshaping breast cancer management. They discuss how this innovative approach enables the detection of molecular disease that may persist after treatment — often before clinical or radiographic signs appear. Research shows MRD testing can iden...

In this episode of OncoTalks, Dr. Ira Zackon, Senior Medical Director at Ontada, is joined by Dr. Marcus Neubauer, Medical Director for Professional Wellbeing at The US Oncology Network, to explore the pressing issue of provider burnout in healthcare. Together, they examine the root causes, personal and organizational impacts, and the importance of fostering a culture where provider well-being is...

In this episode of OncoTalks, Dr. Mia Levy and Dr. Paul Conkling discuss new FDA-approved treatments and therapies for HR-positive, HER2-negative metastatic breast cancer. Discover innovative genomic testing techniques that are changing the identification of mutations, paving the way for more precise treatment strategies. Tune in as we spotlight advancements in personalized breast cancer care and...

Tune into our debut episode of OncoTalks Case Journey as Dr. Paul Conkling and Dr. Mabel Mardones discuss two compelling cases of metastatic ER-positive breast cancer, emphasizing the role of antibody drug conjugates (ADCs) in treatment. They explore the challenges of HER2-low classification and the importance of early access to innovative therapies for improving patient outcomes. The conversation...

In this episode of OncoTalks, Dr. Paul Conkling and Dr. David Cosgrove explore the latest advancements in mCRC treatment, highlighting the shift from traditional chemotherapy to innovative targeted therapies driven by genomic insights. We discuss the role of next-generation sequencing, new therapeutic agents, and clinical trials, while emphasizing personalized care, addressing treatment challenges...

Join us for the conclusion of our 2-part series on HER2-low breast cancer, featuring Dr. Paul Conkling and Dr. Erika Hamilton. They discuss the Phase 1 results from a HER2-low retrospective study evaluating HER2 testing patterns and concordant therapy in patients with HER2 metastatic breast cancer. Learn about the evolving role of HER2-low classification, ongoing education, and treatment strategie...

Join us as we explore the transformative potential of HER2 testing in breast cancer care. In this episode of OncoTalks, Dr. Paul Conkling and Dr. Erika Hamilton share cutting-edge insights that every oncologist should know to stay at the forefront of breast cancer treatment. Tune in to discover how HER2 testing is reshaping the landscape of personalized cancer therapy. Developed and produced by On...

Join Dr. Robert Reid and Dr. Sreeni Chittoor as they explore the revolutionary impact of genomic testing in redefining cancer treatment. We focus on advanced solid tumors, such as non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, examining how these state-of-the-art technologies are leading to more personalized and effective treatment strategies. Developed and produced by O...

Join Dr. Paul Conkling and Dr. Akash Mukherjee as they explore CAR-T Therapy from design of treatment through the patient journey. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Join Dr. Ira Zackon and Dr. David Andorsky on today’s episode of OncoTalks, as they discuss the expanding role of bispecific antibody therapies in the community for Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, Dr. David Waterhouse and Dr. Paul Conkling discuss NSCLC and the groundbreaking developments in treating patients with MET exon 14 (METex14) skipping mutations. We review the science behind these targeted therapies, their clinical applications, and the impact on patient outcomes. Developed and produced by Ontada Learn. The content is intended for educational purposes...

In this episode, Dr. David Waterhouse and Dr. Paul Conkling discuss the evolving landscape of second line treatments for extensive stage small cell lung cancer (SCLC). They review the latest research, promising therapies, and the impact of these treatments on patient quality of life. This episode offers vital information to help navigate treatment options and empower patients. Don’t miss this enga...